Bellicum Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference

HOUSTON–(BUSINESS WIRE)– Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage
biopharmaceutical company focused on discovering and developing novel
cellular immunotherapies for cancers and orphan inherited blood
disorders, today announced that Tom Farrell, President and CEO, will
present at the Ladenburg Thalmann 2016 Healthcare Conference. The
presentation will take place on Tuesday, September 27, 2016 at 10:00
a.m. EDT in New York City.

A live webcast of the presentation may be accessed from the News
& Events section of the Bellicum website. An archived
version of the webcast will be available for replay for at least two
weeks following the event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on
discovering and developing cellular immunotherapies for cancers and
orphan inherited blood disorders. Bellicum is using its proprietary
Chemical Induction of Dimerization (CID) technology platform to engineer
and control components of the immune system. Bellicum is developing
next-generation product candidates in some of the most important areas
of cellular immunotherapy, including hematopoietic stem cell
transplantation (HSCT), and CAR T and TCR cell therapies. More
information can be found at www.bellicum.com.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005082/en/